Gilead’s coronavirus drug remdesivir fails in first trial
Interest in Gilead's drug has been high as there are no approved treatments or preventive vaccines for Covid-19
23 April 2020 - 20:23
Bengaluru — Gilead Sciences's experimental coronavirus drug failed its first randomised clinical trial, the Financial Times reported on Thursday, citing draft documents published accidentally by the World Health Organisation (WHO).
Trading in the shares of the company was halted after they fell 6%...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.